MAP3K5 and metabolic dysfunction-associated steatohepatitis: Inhibition of ASK1 has been reported to attenuate hepatic inflammation and fibrosis in animal models of NASH (Budas et al., 2016), demonstrating that ASK1 represents a potential target for NASH.